RU2769397C2 - Композиции и способы лечения передозировки опиоидами - Google Patents

Композиции и способы лечения передозировки опиоидами Download PDF

Info

Publication number
RU2769397C2
RU2769397C2 RU2019118465A RU2019118465A RU2769397C2 RU 2769397 C2 RU2769397 C2 RU 2769397C2 RU 2019118465 A RU2019118465 A RU 2019118465A RU 2019118465 A RU2019118465 A RU 2019118465A RU 2769397 C2 RU2769397 C2 RU 2769397C2
Authority
RU
Russia
Prior art keywords
patient
pharmaceutical composition
nalmefene
opioid
nalmefene hydrochloride
Prior art date
Application number
RU2019118465A
Other languages
English (en)
Russian (ru)
Other versions
RU2019118465A3 (cg-RX-API-DMAC10.html
RU2019118465A (ru
Inventor
Роджер КРИСТАЛ
Эдвард Т. МАДЖО
Original Assignee
Опиант Фармасьютикалз, Инк.
ЭДЖИС ТЕРАПЬЮТИКС, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62146061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2769397(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Опиант Фармасьютикалз, Инк., ЭДЖИС ТЕРАПЬЮТИКС, ЭлЭлСи filed Critical Опиант Фармасьютикалз, Инк.
Publication of RU2019118465A publication Critical patent/RU2019118465A/ru
Publication of RU2019118465A3 publication Critical patent/RU2019118465A3/ru
Application granted granted Critical
Publication of RU2769397C2 publication Critical patent/RU2769397C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2019118465A 2016-11-18 2017-11-09 Композиции и способы лечения передозировки опиоидами RU2769397C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662424378P 2016-11-18 2016-11-18
US62/424,378 2016-11-18
PCT/US2017/060964 WO2018093666A1 (en) 2016-11-18 2017-11-09 Compositions and methods for the treatment of opioid overdose

Publications (3)

Publication Number Publication Date
RU2019118465A RU2019118465A (ru) 2020-12-18
RU2019118465A3 RU2019118465A3 (cg-RX-API-DMAC10.html) 2021-03-04
RU2769397C2 true RU2769397C2 (ru) 2022-03-31

Family

ID=62146061

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019118465A RU2769397C2 (ru) 2016-11-18 2017-11-09 Композиции и способы лечения передозировки опиоидами

Country Status (9)

Country Link
US (3) US11458091B2 (cg-RX-API-DMAC10.html)
EP (1) EP3541386A4 (cg-RX-API-DMAC10.html)
JP (2) JP7312698B2 (cg-RX-API-DMAC10.html)
CN (1) CN110139651A (cg-RX-API-DMAC10.html)
AU (2) AU2017360910B2 (cg-RX-API-DMAC10.html)
CA (1) CA3044221A1 (cg-RX-API-DMAC10.html)
IL (2) IL312012A (cg-RX-API-DMAC10.html)
RU (1) RU2769397C2 (cg-RX-API-DMAC10.html)
WO (1) WO2018093666A1 (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
WO2018093666A1 (en) 2016-11-18 2018-05-24 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
US20210220346A1 (en) * 2018-05-17 2021-07-22 Aegis Therapeutics Llc Formulations and methods for the prevention of opioid overdose
WO2019231993A1 (en) * 2018-06-01 2019-12-05 Purdue Pharma L.P. Compositions and methods for opioid overdose rescue
US11865112B2 (en) 2018-11-06 2024-01-09 Purdue Pharma L.P. Compositions and methods for opioid antagonist delivery
US20210401827A1 (en) * 2018-11-07 2021-12-30 Opiant Pharmaceuticals, Inc. Methods, parenteral pharmaceutical formulations, and devices for the prevention of opioid overdose
CA3134943A1 (en) 2019-03-26 2020-10-01 Pocket Naloxone Corp. Devices and methods for delivering pharmaceutical compositions
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
CA3167312A1 (en) * 2020-02-07 2021-08-12 Stephen J. Lewis Compositions and methods for attenuating opioid induced cardio and/or respiratory depression
CN115515621A (zh) * 2020-05-04 2022-12-23 安福星制药公司 胆汁酸及其盐作为药物的经鼻递送的增强剂的安全用途
CN121265577A (zh) 2020-05-18 2026-01-06 奥瑞克索股份公司 用于药物递送的药物组合物
US20220111162A1 (en) * 2020-07-29 2022-04-14 Lido Ventures Llc Apparatus, system, and method for facilitating intranasal treatment of a patient
EP4284506A4 (en) * 2021-02-01 2024-12-25 Clear Scientific, Inc. SEQUESTRATION COMPOUNDS FOR THE TREATMENT OF SUBSTANCE USE DISORDER AND USES THEREOF
US20220387407A1 (en) * 2021-02-08 2022-12-08 Case Western Reserve University Compositions and methods for attenuating opioid induced cardio and/or respiratory depression
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
CA3227828A1 (en) 2021-08-04 2023-02-09 Indivior Inc. Compositions and methods for the treatment of opioid overdose
TW202333658A (zh) 2021-11-25 2023-09-01 瑞典商奥瑞克索股份公司 包含腎上腺素之新穎醫藥組合物
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
WO2024010379A1 (ko) * 2022-07-05 2024-01-11 주식회사 지투지바이오 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방성 미립구 제제 및 이의 제조방법
WO2024222920A1 (zh) * 2023-04-28 2024-10-31 成都苑东生物制药股份有限公司 一种用于鼻内给药的药物制剂及其制备方法
WO2025255416A1 (en) * 2024-06-05 2025-12-11 TMTRx, Inc. Fentanyl and fentanyl analogue overdose reversal

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095389A1 (en) * 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration
RU2554814C2 (ru) * 2008-12-22 2015-06-27 ЭДЖИС ТЕРАПЬЮТИКС, ЭлЭлСи Композиции для введения лекарственных средств
US20150258019A1 (en) * 2014-03-14 2015-09-17 Lightlake Therapeutics, Inc. Nasal drug products and methods of their use
US20160166503A1 (en) * 2014-03-14 2016-06-16 Lightlake Therapeutics, Inc. Nasal drug products and methods of their use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US4880813A (en) 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
US5069895A (en) 1989-11-09 1991-12-03 Diamond Ivan F Methods for the treatment of alcohol intoxication and dependence
EP0444778A1 (en) 1990-02-14 1991-09-04 Alcon Laboratories, Inc. Use of alkyl saccharides to enhance the penetration of drugs
US5369095A (en) 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US6271240B1 (en) 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
EP1423116A1 (en) 2001-08-14 2004-06-02 Biotie Therapies Corp. Method of treating alcoholism or alcohol abuse
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US20110257096A1 (en) 2004-08-25 2011-10-20 Aegis Therapeutics, Inc. Compositions for drug administration
CN1305474C (zh) * 2004-10-13 2007-03-21 北京国药龙立生物医药新技术有限公司 盐酸纳美芬鼻腔给药制剂
US20070212307A1 (en) 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US20080090771A1 (en) 2006-10-06 2008-04-17 Shire Llc Abuse-resistant hydrocodone compounds, compositions and methods of using the same
WO2008095086A2 (en) 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
JP2010537990A (ja) 2007-08-27 2010-12-09 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール中毒および薬物嗜癖の処置のための医薬の組み合わせ
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
WO2009128474A1 (ja) 2008-04-16 2009-10-22 財団法人化学及血清療法研究所 トロンビン固定化生体吸収性シート製剤の製造方法
ES2686299T3 (es) 2010-10-29 2018-10-17 Troikaa Pharmaceuticals Ltd Composiciones nasales de vitamina B12
PT3415139T (pt) 2011-06-14 2022-06-20 Neurelis Inc Administração de benzodiazepina
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
US20140171458A1 (en) 2012-12-13 2014-06-19 3B Pharmaceuticals, Inc. Intranasal naltrexone
DE202013105715U1 (de) 2013-08-22 2014-02-19 Sipnose Ltd. Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers
EP3057596A4 (en) 2013-10-14 2017-03-29 Palmaya Pty Ltd Compositions and methods of administering same
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US20160008277A1 (en) 2014-07-09 2016-01-14 Lightlake Therapeutics Inc. Co-packaged drug products
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
NZ750067A (en) * 2016-06-24 2025-11-28 Aegis Therapeutics Llc Compositions, devices, and methods for the treatment of alcohol use disorder
CA3043028A1 (en) 2016-11-09 2018-05-17 Opiant Pharmaceuticals, Inc. Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
WO2018093666A1 (en) 2016-11-18 2018-05-24 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose
CN106361700A (zh) 2016-11-25 2017-02-01 威海恒基伟业信息科技发展有限公司 盐酸纳美芬鼻腔给药制剂
US20210220346A1 (en) 2018-05-17 2021-07-22 Aegis Therapeutics Llc Formulations and methods for the prevention of opioid overdose
US20210401827A1 (en) 2018-11-07 2021-12-30 Opiant Pharmaceuticals, Inc. Methods, parenteral pharmaceutical formulations, and devices for the prevention of opioid overdose
WO2020132263A1 (en) 2018-12-20 2020-06-25 Aegis Therapeutics, Inc. Compositions, devices, and methods for the treatment of overdose and reward-based disorders
US20200390691A1 (en) 2018-12-20 2020-12-17 Aegis Therapeutics, Inc. Compositions, devices, and methods for the treatment of overdose and reward-based disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2554814C2 (ru) * 2008-12-22 2015-06-27 ЭДЖИС ТЕРАПЬЮТИКС, ЭлЭлСи Композиции для введения лекарственных средств
WO2015095389A1 (en) * 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration
US20150258019A1 (en) * 2014-03-14 2015-09-17 Lightlake Therapeutics, Inc. Nasal drug products and methods of their use
US20160166503A1 (en) * 2014-03-14 2016-06-16 Lightlake Therapeutics, Inc. Nasal drug products and methods of their use

Also Published As

Publication number Publication date
US20200060967A1 (en) 2020-02-27
IL266674B1 (en) 2024-05-01
IL266674A (en) 2019-07-31
AU2017360910B2 (en) 2023-11-23
WO2018093666A1 (en) 2018-05-24
JP7312698B2 (ja) 2023-07-21
IL266674B2 (en) 2024-09-01
IL312012A (en) 2024-06-01
EP3541386A4 (en) 2020-05-27
CN110139651A (zh) 2019-08-16
AU2024201047A1 (en) 2024-03-14
US20220387306A1 (en) 2022-12-08
JP2023140359A (ja) 2023-10-04
US20250127712A1 (en) 2025-04-24
RU2019118465A3 (cg-RX-API-DMAC10.html) 2021-03-04
JP7730443B2 (ja) 2025-08-28
AU2017360910A1 (en) 2019-05-30
EP3541386A1 (en) 2019-09-25
CA3044221A1 (en) 2018-05-24
JP2019534315A (ja) 2019-11-28
RU2019118465A (ru) 2020-12-18
US11458091B2 (en) 2022-10-04

Similar Documents

Publication Publication Date Title
JP7730443B2 (ja) オピオイド過剰摂取を処置するための組成物および方法
JP7492548B2 (ja) アルコール使用障害の処置のための組成物、装置、及び、方法
US20210077382A1 (en) Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
US20260021038A1 (en) Compositions and Methods for the Treatment of Opioid Overdose
US20240197719A1 (en) Formulations and methods for the prevention of opioid overdose
WO2020097279A1 (en) Methods, parenteral pharmaceutical formulations, and devices for the prevention of opioid overdose
JP2024164155A (ja) 過剰摂取および報酬に基づく障害を処置するための、組成物、装置、および方法
US20240408004A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
US20200390691A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
US20240408003A1 (en) Compositions, devices and methods for the treatment of alcohol use disorder